

In certain cases, Elderplan may require a member to try a **Step 1 (Preferred) Drug** to treat their medical condition before proceeding to a **Step 2 (Non-Preferred) Drug**. Our Step 1 (Preferred) Drugs promote therapeutic effectiveness and are low in drug cost.

Part B Drug Step Therapy does **not** apply to a member if the member has already been receiving treatment with a Non-Preferred Drug in the past 365 days. If a member is new to treatment, and the provider determines that a Non-Preferred Drug is the best fit for the member, the provider may request a Non-Preferred Part B Drug.

Instructions on how to request a Non-Preferred Part B Drug can be found on our Provider Web Portal at www.elderplan.org/for-providers/ or on our website at www.elderplan.org/for-providers/provider-materials/.

Non-Preferred Part B Drug Requests may be faxed to 929-275-3223.

The table below displays the drug classes included in Elderplan’s Part B Drug Step Therapy Program effective January 1st, 2022*.

Drug Class	Step 1 Drugs (Preferred)	Step 2 Drugs (Non-Preferred)
Bevacizumab	Avastin Mvasi Zirabev	None
Hematologic, Neutropenia Colony Stimulating Factors – Long Acting	Neulasta Udenyca	Fulphila Nyvepria Ziextenzo
Hematologic, Neutropenia Colony Stimulating Factors – Short Acting	Zarxio	Granix Leukine Neupogen Nivestym
Multiple Sclerosis (Infused)	Tysabri	Lemtrada
Trastuzumab	Herceptin Herceptin Hylecta Kanjinti Trazimera	Herzuma Ogivri Ontruzant

* This Part B Drug list may be subject to change throughout the year. Non-preferred product(s) are only available if process exception criteria are met. This list indicates the common uses for which the drug is prescribed. Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with Elderplan. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.